Studies of CML patients on imatinib mesylate (IM) treatment for >4 years indicate BCR-ABL+ cells are retained in the primitive CD34+ CD38− population, even when a deep molecular response is achieved, thus CML LSC are not eradicated6,7. The gene discussed is CD38; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.